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Summary
Background: Exclusive enteral nutrition (EEN) is an effective treatment for Crohn's 
disease.
Aims: To investigate the hypothesis that ingredients of EEN formulas are unlikely to 
initiate a disease flare and that their dietary elimination is not essential for disease 
amelioration.
Methods: We performed compositional analysis of EEN formulas with evidence of 
efficacy in management of active Crohn's disease. Macronutrient content was com-
pared against the dietary reference values (DRV), the UK National Diet and Nutrition 
Survey (NDNS) and intake of Crohn's disease children. Food additives were cross-
referenced against the FAO/WHO database.
Results: Sixty-one formulas were identified with variable composition (carbohydrates 
[22.8%-89.3%], protein [7.8%-30.1%], fat [0%-52.5%]). Maltodextrin, milk protein and 
vegetable/plant oils were the commonest macronutrient sources. Their n-6:n-3 fatty 
acid ratio varied from 0.25 to 46.5. 56 food additives were identified (median per for-
mula: 11). All formulas were lactose-free, gluten-free, and 82% lacked fibre. The com-
monest food additives were emulsifiers, stabilisers, antioxidants, acidity regulators 
and thickeners. Food additives, implicated in Crohn's disease aetiology, were present 
in formulas (modified starches [100%], carrageenan [22%], carboxymethyl cellulose 
[13%] and polysorbate 80 [5%]). Remission rates did not differ between EEN formulas 
with and without those food additives. Analysis including only formulas from ran-
domised controlled trials (RCTs) retained in the latest Cochrane meta-analysis pro-
duced similar findings. EEN formulas contained less energy from saturated fat than 
NDNS intake.
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1  | INTRODUC TION
Inflammatory bowel disease (IBD) is more prevalent in Western 
countries and its incidence is increasing, particularly in low- and me-
dium-income countries which are in financial transition, and in those 
who adopt a Western lifestyle.1 This points to an environmental dis-
ease trigger, as the rapid increase in incidence outpaces changes in 
transcriptional human genetics.
Epidemiological evidence from observational studies has impli-
cated certain dietary macronutrients, such as polyunsaturated fatty 
acids (PUFA) and fibre, in IBD onset,2 but dietary intervention stud-
ies, based on this evidence, have been unable to reverse the disease 
course and induce or maintain disease remission in patients with 
IBD.3,4 In preclinical studies in animal models, a diet high in total fat 
and sugars aggravated inflammatory response, induced intestinal 
dysbiosis, promoted overgrowth of pro-inflammatory Proteobacteria 
with a parallel decrease in protective members of the gut microbi-
ome, reduced production of short chain fatty acids and suppressed 
the mucosal expression of their G-protein coupled receptor 43.5
Our habitual diet has evolved enormously in recent decades, not 
only in terms of nutrient composition but also, importantly, in terms of 
nonnutrient food ingredients used in food preservation and process-
ing. Although food industrialisation has safeguarded humans from in-
fectious diseases and increased food durability, availability and global 
accessibility, the effect this may have on host health and the onset of 
noncommunicable diseases is now becoming clearer. Recent studies 
in animal models have indicated that food additives might affect co-
lonic and cardiovascular health, mediated by their effects on the gut 
microbiome, the mucus layer, the gut barrier function and the gut as-
sociated immune system.6,7 Dietary emulsifiers, such as polysorbates 
and carboxymethyl cellulose have been shown to increase intestinal 
permeability, alter microbiome composition, promote Escherichia coli 
translocation across the intestinal epithelium and cause gut inflamma-
tion in M cells in vitro and in animal experiments.6-10
Such epidemiological and preclinical observations have quickly 
been translated to dietary recommendations and presumptive thera-
pies for the management of IBD.7 However, it is important to accept 
that there are currently no well-controlled intervention studies in hu-
mans to prove that exposure to food additives increases risk of IBD 
onset, or indeed aggravates gut inflammation in those with the illness. 
Likewise, there are no intervention studies to prove that exclusion of 
food additives, sugars or milk fat mitigates colonic inflammation in IBD 
patients or that their introduction to the diet of patients with disease 
in remission initiates disease flare. On the contrary, data from a dietary 
intervention showed that among patients with Crohn's disease in re-
mission, the levels of red and processed meat consumption were not 
associated with time to symptomatic relapse.11
Exclusive enteral nutrition (EEN), a liquid-only diet using propri-
etary formula, is the only effective and established dietary treatment 
which induces remission in active Crohn's disease. It is the first-line 
treatment for children with active Crohn's disease throughout Europe, 
Oceania and parts of North America.12 Treatment with EEN for 
8 weeks induces clinical remission and disease improvement in approx-
imately 80% of children with active Crohn's disease and suppresses 
colonic inflammation.13-15 The EEN formulas used for the management 
of Crohn's disease are extensively industrialised products which vary 
considerably in terms of their composition of nutrients and nonnutri-
ent food ingredients, including food additives. It is therefore possible 
to use the compositional profile of EEN formulas, shown to induce 
remission in Crohn's disease, to elicit clues about the role of various 
food components in the disease course. We hypothesise that nutrients 
and food ingredients which are included in one or more EEN formulas 
with clinical efficacy data in the management of active Crohn's disease 
are unlikely to play a major role in the disease course and are there-
fore unlikely to initiate or sustain a disease flare in Crohn's disease. 
Conversely, nutrients and food additives, or other nonnutrient food 
ingredients, which are both specifically absent from the composition 
of EEN formulas (eg lactose, gluten), and whose hypothetical inflam-
matory mechanism is supported by preclinical data, warrant further 
exploration of their role in Crohn's disease.
We performed an extensive nutrient, nonnutrient food ingredi-
ent and food additive compositional analysis of EEN formulas with 
published evidence of clinical efficacy in the management of ac-
tive Crohn's disease. Subsequently, we compared the composition 
of EEN formulas with the UK dietary reference values (DRV), the 
dietary intake of children from the UK National Diet and Nutrition 
Survey (NDNS), the dietary intake of a group of children with 
Crohn's disease and against published preclinical evidence which im-
plicates food additives and nonfood ingredients in Crohn's disease 
pathogenesis.
2  | METHODS
2.1 | Search strategy
An extensive literature search was carried out using the MEDLINE da-
tabase (from inception to July 2019) with the search terms ("Crohn*" 
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OR "inflammatory bowel disease") AND ("enteral nutrition" OR "nu-
tritional support"), Figure 1. The search yielded 984 articles. Three 
researchers (ML, KG and VS) independently reviewed the articles, 
and a manual search of the reference lists of the identified studies 
was also undertaken to identify additional EEN formulas. Studies 
not carried out in humans, not in English, not available as full text 
and/or not providing the brand of EEN formula used were excluded. 
Studies which reported use of enteral nutrition formulas solely for 
maintenance of remission in Crohn's disease, nutritional support and/
or rehabilitation of malnutrition were excluded. EEN formulas, which 
were manufactured specifically for the purposes of clinical research, 
but have not been used in clinical practice, were also excluded. EEN 
formulas were considered eligible for inclusion, only if they were used 
for induction of remission in active Crohn's disease. Clinical efficacy 
of EEN formulas in the included studies was evaluated based on im-
provement of at least one of the following parameters:
1. Established clinical activity indices (eg weighted paediatric 
Crohn's disease activity index, Harvey-Bradshaw index) or 
global physicians’ assessment/impression;
2. Endoscopic scores (eg simple endoscopic scores-Crohn's disease) 
often coupled with histology;
3. Faecal calprotectin;
4. Radiological scores;
5. Biochemical indices, such as C-reactive protein, erythrocyte sedi-
mentation rate and albumin.
Clinical remission rate (percentage of patients entering remis-
sion) was the most commonly reported outcome of EEN formula ef-
ficacy and was recorded for each study and for each EEN formula, 
when these data were available.
In total, 71 different EEN formulas which reported clinical effi-
cacy were identified and their brand names recorded. Five formu-
las were excluded as they were each used in only one patient. Five 
other formulas were excluded as nutritional information could not 
be retrieved, Table S1. This left 61 EEN formulas in the final anal-
ysis, extracted from 94 studies, Figure 1. An evidence table with 
all the included studies and associated information is presented as 
Supplementary material 1. Data of efficacy of included EEN formu-
las are presented in Table S2.
F I G U R E  1   Flowchart of search strategy to identify EEN formulas with published evidence of efficacy in the induction of remission in 
active Crohn's disease
Records identified through database
searching
(n = 984)
Non-English records
excluded
(n = 178)
Records excluded: Reviews,
abstracts
(n = 637)
Records excluded: EEN formula brand not
given,EEN formula not used as induction of
remission therapy
(N = 75)
Studies included documenting EEN formula
branding information when used as
induction therapy
(n = 94)
Records screened
(n = 806)
Full text articles assessed for eligibility
(n = 169)
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2.2 | Collection of nutritional information and list of 
food additives from EEN formulas
Nutritional information for each formula was extracted from the 
manufacturer's product data information sheet. Formulas with the 
same name (eg Peptamen®) which were used in more than one 
country, but contained different ingredients were considered indi-
vidually as separate formulas. For six formulas (Edanec HN, Flexical, 
Fortison, Pepdite 2+, Pepti-2000 LF liquid and Realmentyl), nutri-
tional information was retrieved from journal articles. For EEN for-
mulas which were used in the past but are not currently available, 
the most recent EEN formula was used (eg Vivonex – Vivonex TEN). 
Most of the EEN formulas presented in this study were used unfla-
voured. For formulas which are available with different flavours, we 
chose the vanilla flavour for consistency, unless this flavour was not 
available. Food additives from each EEN formula were cross-refer-
enced against the FAO/WHO food standards Codex Alimentarius 
database, general standards for food additives (GSFA).16 The GSFA 
is a standardised database of food additives, permitted to be used in 
foods, grouped into 27 different functional classes. Each food addi-
tive identified within the EEN formulas was assigned to its functional 
class. Food additives implicated in IBD pathogenesis were identi-
fied from major recent reviews in the topic6,17 and any additional 
evidence from published primary research.18 From the studies which 
reported remission rates (eg percentage of patients entering remis-
sion), median differences in remission rates between EEN formulas 
which contain these implicated food additives and those which do 
not were compared.
Subgroup analysis was performed, in which we examined only 
the EEN formulas which were used in at least one of the RCTs re-
tained in the most recent Cochrane meta-analysis of efficacy of EEN 
in active Crohn's disease.19 We followed this approach to select only 
EEN formulas trialled within an RCT.
2.3 | Comparison of macronutrient composition of 
EEN formulas against the NDNS, The UK DRV and a 
contemporary cohort of children with Crohn's disease
Since EEN is predominantly used in paediatric practice at present, 
the macronutrient content (fat, carbohydrate, protein and their indi-
vidual forms) of each EEN formula was standardised to the average 
energy requirements of a 10-year-old child (ie 2000 kcal) to enable 
comparison between them. The proportional ratio of each macro-
nutrient in EEN formulas was then compared against the Western 
diet intake of a representative cohort of healthy UK children who 
participated in the rolling programme of the NDNS [Years 1-8 
(2008-2014),20 and also against the UK DRV for children. As there 
are different DRV for fibre per age group, an average of the DRV 
for fibre for children aged 5-18 was used (ie 25 g/d). The DRV for 
protein, total fat and carbohydrates were 15%, 35% and 50% of en-
ergy intake respectively. Likewise, the macronutrient intake from 
the NDNS was expressed as percentage of energy intake and was 
derived by averaging the intakes of the two available age ranges for 
children (ie children 4-10 years and children 11-18 years). In addi-
tion to this analysis, we compared the macronutrient content of the 
EEN formulas against a cohort of children with established Crohn's 
disease, whose dietary habits we have previously described.21 Since 
fibre intake in that Crohn's disease cohort was reported as nonstarch 
polysaccharides (NSP), we used the conversion factor (1.33) to con-
vert NSP to fibre, as measured by the association of official analytic 
chemists (AOAC), as fibre content in EEN formulas is reported as 
AOAC fibre.22
2.4 | Statistical analysis
Descriptive statistics are presented as median with interquartile 
range, unless otherwise stated. The macronutrient intake of EEN for-
mulas, expressed as percentage of energy, was compared against the 
NDNS data and the UK DRV using 1-sample sign tests. Comparisons 
between the macronutrient content of the EEN formulas and the di-
etary intake of children with Crohn's disease were performed using 
Mann-Whitney test. Differences in median remission rates between 
EEN formulas which contain these food additives and those which 
do not were explored with the Mann-Whitney test. Statistical analy-
sis was conducted using Minitab version 18 (Minitab, Ltd). P < 0.05 
were considered statistically significant. The presence/absence of 
food additives within EEN formulas for each GSFA food additive cat-
egory was visualised using the pheatmap (version 1.0.12) package in 
R (version 3.5.2).
3  | RESULTS
3.1 | Nutritional composition analysis of EEN 
formulas
Sixty-one formulas used for induction of remission in active Crohn's 
disease were included in the final analysis. Of these formulas, 39/61 
(64%) were polymeric, 16/61 (26%) were semi-elemental and the re-
maining 6/61 (10%) were elemental. Fifty-one out of sixty-one (84%) 
formulas were labelled as gluten-free and 52/61 (85%) as “clinically 
lactose-free”; information regarding gluten and lactose content was 
unavailable for the remaining 10/61 (16%) and 9/61 (15%) EEN for-
mulas respectively.
The different sources of protein, fat, carbohydrates and fibre 
included in the EEN formulas are presented in Figure 2. For three 
formulas (Edanec HN, Pepti-2000LF liquid and Realmentyl), informa-
tion regarding the source of fat was unavailable and for one formula 
(Realmentyl), the source of carbohydrates was also unavailable. One 
other formula (Ensure®, USA) presented micronutrient content only 
as percentage of DRV per 2000 kcal, hence only its macronutrient 
content was considered for analysis. For six formulas (Edanec HN, 
Flexical, Fortison, Pepdite 2+, Pepti-2000 LF liquid and Realmentyl), 
the complete ingredient list could not be retrieved.
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All but one polymeric and one semi-elemental formula contained 
at least one protein source derived from milk. Of these two, the 
semi-elemental formula (Pepdite 2+) contained meat protein and 
the polymeric formula (Realmentyl) contained both meat and egg 
protein. Of the 55 polymeric and semi-elemental EEN formulas, 
33 (60%) contained both casein and whey protein. Seven out of 55 
formulas (13%) contained only casein, and 13/55 (24%) only whey 
protein. Sixteen out of fifty-five (29%) EEN formulas also contained 
soy protein; protein from peas was found in 3/55 (5%) formulas. The 
main sources of fat in the 58 EEN formulas for which information 
could be retrieved, included sunflower oil (22/58 [38%]), canola oil 
(18/58 [31%]), soybean oil and rapeseed oil (15/58 [26%]), fish oil 
(13/58 [22%]), corn oil (11/58 [19%]) and palm oil (10/58 [17%]). Two 
out of fifty-eight (3%) EEN formulas did not contain any fat. From 
the 60 formulas which reported the source of carbohydrates, malto-
dextrin was the most common, (47/60 [78%]), followed by sucrose, 
which was present in 31/60 (52%) formulas. Glucose syrup, a prod-
uct of starch hydrolysis, was present in 12/60 (20%) and unspecified 
derivatives of corn starch in 9/60 formulas (15%), Figure 2.
From the 55 EEN formulas, for which complete ingredient list 
was retrieved, 10/55 (18%) contained fibre, such as inulin, fruc-
to-oligosaccharides, pectin and gum arabic. Guar gum was listed as 
an ingredient in 7/55 (13%) EEN formulas, but only in one of them 
(Peptamen® junior 1.5), it was a specified source of fibre.
All EEN formulas contained essential vitamins, minerals and 
trace elements, the content of which varied considerably amongst 
them, Table S3. Some contained nonnutrient food ingredients, such 
as nutraceuticals, including taurine (27/55 [49%]), L-carnitine (25/55 
[45%]), inositol (9/55 [16%]), nucleic acids (2/55 [4%]) and probiotics 
(1/55 [2%]). A detailed ingredient list of the identified formulas is 
presented as Supplementary material 2.
Macronutrient content varied substantially among the various 
EEN formulas, Table S3. For carbohydrates, this ranged from 22.8% 
to 89.3%, for protein from 7.8% to 30.1% and for total fat from 0% 
to 52.5%. Likewise, the intake of sugars varied from 2.5% to 55.0% 
and saturated fat from 0% to 28.6. There was a wide variety in the 
type of fatty acids contained in the various EEN formulas. Twenty-
six out of sixty one (43%) reported the content of monounsaturated 
fatty acids and PUFA, with 30/61 (49%) containing medium chain 
triglycerides, 8/61 (13%) reporting eicosapentaenoic acid and 10/61 
(16%) docosahexaenoic acid. Of the 24/61 (39%) EEN formulas which 
reported the concentration of medium chain triglycerides, their con-
tent per 2000 kcal ranged from 4.7 to 60 g, with a median content of 
20.0 (Q1: 12.0, Q3: 52.0). The n-6: n-3 fatty acid ratio was available 
in 30/61 (49%) EEN formulas, varying considerably between 0.25 to 
46.5, with a median ratio of 4.1 (Q1: 2.8, Q3: 46.5).
3.2 | Food additives in EEN formulas
Of the 61 identified EEN formulas, information pertinent to food 
additives was available from 55 (90%) of these. In total, 56 unique 
F I G U R E  2   Sources of carbohydrates, fat, protein and fibre in EEN formulas used for induction of clinical remission in patients with active 
Crohn's disease, as this is reported on the nutritional information label of the EEN formula. Blue: All EEN formulas identified; Green: EEN 
formulas of RCTs retained in Cochrane meta-analysis
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food additives matched against the GSFA database were identi-
fied, Figure 3. Maltodextrin, dextrins, glucose syrup, corn syrup 
and modified starch were grouped under the same term: modified 
starch. From the food additives identified within the EEN formu-
las surveyed in this study, the 56 unique food additives could be 
grouped into 23/27 (85%) of the unique functional classes from the 
GSFA database, Figure 3. Of these food additives, 38/56 (68%) were 
presumed to have been used primarily to improve the organoleptic 
(ie sensory) characteristics and for preservation of the EEN formu-
las, as no direct nutritional value could be attributed to them. Of the 
remaining 18/56 (32%), it was unspecified whether these had been 
included as food additives or as nutrient supplements, Figure 3.
F I G U R E  3   Heatmap of food additives and their associated General Standard for Food Additives functional classes contained in EEN 
formulas used in the literature for induction of clinical remission in patients with active Crohn's disease. i, All EEN formulas identified; ii, 
EEN formulas of RCTs retained in the Cochrane meta-analysis; A, Food additives with no nutritional value, B, Food additives with nutritional 
value
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Each EEN formula contained a median of 11 (Q1: 9, Q3: 13, 
min: 6, max: 16) unique food additives; with a median of four (Q1: 
3, Q3: 5) additives used for organoleptic purposes and food pres-
ervation, while a median of seven (Q1: 5, Q3: 8) additives may 
have also been used as nutrient supplements. Modified starch, a 
food additive with nutritional value as carbohydrate source, was 
the most common and was identified in all formulas included in 
this analysis, Figure 3.
In subsequent analysis, we chose to focus only on the 38 food 
additives which are less likely to bear any nutritional value, and 
therefore are used primarily as food additives and not as nutri-
tional supplements. Of the 23 functional classes of food additives, 
the five most common were emulsifiers, stabilisers, antioxidants, 
acidity regulators and thickeners, Figure 3. The ten most com-
mon food additives present in the 55 EEN formulas apart from 
modified starch (present in all EEN formulas), were soy lecithin 
(n = 38, [69%]), citric acid (n = 26, [47%]), unspecified natural 
and artificial flavour (n = 23, [42%]), mono- and diglycerides of 
fatty acids (n = 13, [24%]), carrageenan and potassium hydroxide 
(n = 12, [22%]). Calcium and magnesium hydroxide were present in 
nine (16%) EEN formulas, calcium chloride in eight (15%) and car-
boxymethyl cellulose (cellulose gel) and phosphoric acid in seven 
(13%) EEN formulas, Figure 3.
3.3 | Food additives and other ingredients 
implicated in IBD in preclinical research
In recently published research, maltodextrin, carboxymethyl cellu-
lose, polysorbate 80, carrageenan, inorganic phosphates, sucralose 
and microparticles such as aluminium silicate and titanium dioxide 
were reported as causative agents in gut inflammation in animal 
models and in vitro experiments, and by extension have been im-
plicated in IBD onset and disease management.6,17 Modified starch, 
including maltodextrin, was present in all EEN formulas, carra-
geenan was present in 12/55 (22%), carboxymethyl cellulose was 
present in 7/55 (13%) and sucralose and polysorbate 80 were pre-
sent in 3/55 (5%) EEN formulas, Table 1. No EEN formula contained 
titanium dioxide or propionic acid salts; the latter has been shown 
to serve as a potential mediator for pro-inflammatory action of ad-
herent-invasive E coli,18 Table 1. Inorganic phosphates, compounds 
such as phosphoric acid or phosphate salts (sodium, magnesium, 
calcium and potassium phosphates) were found in 49/54 (91%) of 
the EEN formulas, Table 1. Soy lecithin has been implicated in IBD 
pathogenesis, due to its pro-inflammatory potential in animals fed 
high fat diets,23 although clinical trials in patients with ulcerative 
colitis have shown that soy lecithin can help maintain intestinal 
mucosal integrity.24,25 Soy lecithin was the second most abundant 
TA B L E  1   Dietary components and food additives implicated in IBD based on preclinical evidence from animal experiments and in vitro 
models, and their presence in EEN formulas used for induction of clinical remission in patients with active Crohn's disease
Dietary components 
implicated in IBD 
Presence/ 
Absence 
Percentage presence of dietary components in EEN
formulas 
Proporon of EEN 
formulas containing 
dietary components* 
Modified starch 
 60/60 
 19/19
Inorganic Phosphates 49/54 13/14
Maltodextrin 47/60 13/19
Soy lecithin 38/55 7/15
Carrageenan 12/55 0/15
Carboxymethyl cellulose 7/55 3/15
Sucralose 3/55 0/15
Polysorbate 80 3/55 2/15
Titanium dioxide 0/55 
Aluminium 0/55 
Gluten 0/51 
Lactose 0/52 
Propionic acid 0/55
Abbreviaons: EEN, exclusive enteral nutrion; IBD, inflammatory bowel disease; * The denominator states the number of EEN formulas 
informaon regarding presence/absence of relevant dietary component was available; All EEN formulas: ; EEN formulas used in Cochrane 
review sub-analysis:  
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food additive, present in 38/55 EEN formulas (69%). Gluten, which 
has been associated with disease pathogenesis in preclinical stud-
ies,6 was not present in any of the EEN formulas surveyed here, 
Table 1.
For 24 EEN formulas used in previous research, their exact re-
mission rates were reported separately to that of other formulas. For 
the remaining EEN formulas, their exact remission rates were either 
not reported (n = 4), or for those studies which used multiple EEN 
formulas and reported only the cumulative remission rates (n = 33), 
it was impossible to extract this information.
Within these 24 formulas, median remission rates did not differ 
significantly between EEN formulas containing maltodextrin, soy 
lecithin, carboxymethyl cellulose, polysorbate 80 and carrageenan, 
compared to those which did not contain these food additives 
(median [Q1, Q3] remission rates [%], maltodextrin presence: 72 
[47, 81] vs absence: 69 [52, 79], P = 0.63; soy lecithin presence: 77 
[59, 81] vs absence: 69 [42, 80], P = 0.26; carboxymethyl cellulose 
presence: 71 [41, 88] vs absence: 71 [55, 80], P = 0.97; polysorbate 
80 presence: 77 [59, 85] vs absence: 71 [54, 80], P = 0.61; carra-
geenan: presence: 78 [70, 89] vs absence: 71 [53, 80], P = 0.25), 
Figure 4. As all but one of the EEN formulas contained inorganic 
phosphates, and sucralose was absent from all EEN formulas for 
which reported remission rates could be assigned, it was not pos-
sible to compare efficacy rates between EEN formulas containing 
these food additives.
3.4 | Comparison of EEN macronutrient 
composition with the NDNS intake of children
Compared with the NDNS data of UK children on a Western diet, 
which describe the dietary intake of a representative population of 
UK children, there was no significant difference in the median pro-
portion of energy from carbohydrates, protein, total fat and sugars, 
between EEN formulas and the intake from the NDNS. Conversely, 
the median percentage of energy derived from saturated fat in EEN 
formulas was lower by 7.7% (P = 0.001), and the median fibre intake 
by 25 g (P < 0.001), compared to the NDNS intake, Figure 5.
3.5 | Comparison of EEN macronutrient 
composition with the UK DRV for children
The macronutrient composition of the EEN formulas was also com-
pared against the UK DRV, the national dietary recommendations, 
Figure 5. The median proportion of energy from total and saturated 
fat from the EEN formulas was lower than the upper recommended 
intake (total fat DRV < 35% vs % total fat EEN formulas: 33.6 [27.6, 
36.0], P = 0.04; saturated fat DRV: < 11% vs % saturated fat EEN 
formulas: 4.9 [3.6, 12.7], P < 0.01), whereas no statistical difference 
was found for protein (protein DRV: 15% vs % protein EEN formulas: 
15.7 [11.9, 16.6], P = 0.31). The median energy derived from sugars 
F I G U R E  4   Comparison of remission rates induced by EEN formulas containing food additives implicated in inflammatory bowel disease 
with remission rates induced by EEN formulas not containing these food additives. A, All EEN formulas identified, B, EEN formulas of RCTs 
retained in Cochrane meta-analysis
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was increased in the EEN formulas compared with UK DRV recom-
mendations (sugars DRV: 5% vs % sugars EEN formulas: 12.4 [4.2, 
18.3], P = 0.02), Figure 5. The relative contribution of carbohydrates 
to energy content was higher in EEN formulas than the DRV recom-
mendations (CHO DRV: 50% vs % CHO EEN formulas: 53.9 [49.1, 
55.6], P = 0.04), Figure 5. EEN formulas contained significantly less 
fibre compared to the UK DRV for fibre (Fibre DRV: >25 g/d vs g 
fibre EEN formulas: 0 [0, 0], P < 0.001), Figure 5.
3.6 | Comparison of EEN macronutrient 
composition with the intake of children with Crohn's 
disease on habitual diet
When the nutrient content of EEN formulas was compared with the 
dietary intake of a cohort of children with longstanding Crohn's dis-
ease (n = 45), reanalysed from data drawn from a previous study,21 
there was no difference in the percentage of energy from carbohy-
drates (% CHO; Crohn's disease patients: 52.5 [50.2, 56.2], vs EEN 
formulas 53.9 [49.1, 55.6], P = 0.19), Figure 5. In Crohn's disease pa-
tients, a higher percentage of energy was derived from sugars, total 
fat and saturated fat compared to EEN formulas (% sugars; Crohn's 
disease patients: 25.3 [21.7, 28.7] vs EEN formulas: 12.4 [4.2, 8.3], 
P < 0.001; % total fat; Crohn's disease patients: 35.7 [32.2, 38.8] vs 
EEN formulas: 33.6 [27.6, 36.0], P = 0.04; % saturated fat; Crohn's 
disease patients: 15.9 [13.8, 17.1] vs EEN formulas: 4.93 [3.6, 12.7], 
P < 0.001), Figure 5. Conversely, EEN formulas contained signifi-
cantly more energy derived from protein than Crohn's disease pa-
tients (% protein; Crohn's disease patients: 13.4 [11.3, 15] vs EEN 
formulas: 15.7 [11.9, 16.6], P = 0.04). EEN formulas fibre content was 
significantly lower than the intake of Crohn's disease patients (fibre, 
g; Crohn's disease patients: 10.8 [9, 12.9] vs EEN formulas: 0.0 [0.0, 
0.0], P < 0.001), Figure 5.
3.7 | Subgroup analysis including only EEN formulas 
from RCTS retained in cochrane meta-analysis
Twenty unique EEN formulas had been used in at least one of the 
RCTs retained in the latest Cochrane meta-analysis.19 This subset 
of EEN formulas had similar sources of macronutrients as with the 
full set of 61 EEN formulas presented above. Maltodextrin and milk 
protein were the commonest sources of carbohydrates and protein, 
respectively, while coconut oil was the most common source of fat 
used, Figure 2. One single formula contained fibre (7%), in the form 
of fructo-oligosaccharides.
There was a substantial variation in the macronutrient content 
of these EEN formulas, as was similarly identified when considering 
F I G U R E  5   Macronutrient content of EEN formulas used for induction of clinical remission in patients with active Crohn's disease, intakes 
of children with Crohn's disease and from the general population (4-18 years) of the National Diet and Nutrition Survey, along with the UK 
dietary reference values. Footnote: p-value in blue indicates comparison of “All EEN formulas” with dietary reference values (DRV) and in red 
indicates comparison with the National Diet and Nutrition Survey (NDNS)
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all EEN formulas together (Table S3). Information pertinent to food 
additives content was available for 15/20 (75%) of the Cochrane me-
ta-analysis subset, with a total of 43 food additives present, Figure 3. 
Apart from carrageenan and sucralose, all other food additives cur-
rently implicated in Crohn's disease pathogenesis were present in 
all these EEN formulas, Table 1. Within this group of 20 formulas, 
we found no difference in median remission rates between those 
EEN formulas which contained food additives implicated in Crohn's 
disease and others which did not, Figure 4.
EEN formulas which were included in the Cochrane meta-anal-
ysis provided significantly more energy from saturated fat (% en-
ergy saturated fat, All EEN formulas: 4.9 [3.6, 12.7] vs Cochrane EEN 
formulas: 13.7 [8.1, 22.1], P = 0.001), and significantly less energy 
from sugars (% energy sugars, All EEN formulas: 12.4 [4.2, 18.3] vs 
Cochrane EEN formulas: 7.3 [3.7, 8.8], P = 0.002) than the set of all 
61 EEN formulas, Figure 5. No other statistically significant differ-
ences in macronutrient content (expressed as % of energy) were 
observed between all 61 EEN formulas and those analysed in the 
Cochrane meta-analysis.
4  | DISCUSSION
In this study, we report the macronutrient, nonnutrient food ingredi-
ent and food additive composition of EEN formulas with published 
evidence of clinical effectiveness in the management of active 
Crohn's disease. The extensive variation in the content of these in-
gredients, in EEN formulas, as well as the wide food sources they 
originate from, propose that these dietary constituents are unlikely 
either to be a core mechanism of action of EEN or to comprise a sig-
nificant disease dietary trigger; at least within the amounts these are 
received as part of an EEN course. Similarly, the widespread pres-
ence of food additives in the EEN formulas, including those which 
have been associated with IBD onset within in vitro studies and in 
animal experiments, and the similar clinical remission rates obtained 
irrespective of their presence in EEN formulas, challenge current 
perceptions about their putative role in the dietary management 
of active Crohn's disease by exclusion of these food ingredients.6 
Subgroup analysis including only EEN formulas from RCTs retained 
in the latest Cochrane meta-analysis, to ascertain selection of high-
quality research, produced similar results with the initial set of all 
formulas.
It is well recognised that preclinical data are often not replicated 
in clinical research. For example inorganic microparticles, such as ti-
tanium dioxide 26 and aluminium silicates,27 have been implicated in 
Crohn's disease pathogenesis, with evidence deriving from animal 
studies showing that administration of titanium dioxide microparti-
cles can elicit abnormal intestinal immune response and exacerbate 
colitis in mice.28,29 However, treatment with a low microparticle diet 
for 16 weeks in an RCT did not achieve lower remission rates nor 
decreased faecal calprotectin levels when compared to a normal mi-
croparticle diet in adults with active Crohn's disease.30 Maltodextrin, 
carrageenan, carboxymethyl cellulose and polysorbate 80 have all 
been associated with gut inflammation and, similarly, administration 
of glycerol monolaurate, one of the monoglycerides included in the 
broader food additive category of mono and diglycerides of fatty 
acids, has been shown to induce microbiota perturbation and low 
systemic inflammation in animal studies.9,31-33 However, we have 
shown here that all EEN formulas, which reported their carbohy-
drate source, contain excessive amount of modified starches, includ-
ing maltodextrin, which are disproportionately higher than a healthy 
person would potentially consume daily as part of their habitual diet. 
Furthermore, monoglycerides and diglycerides of fatty acids were 
present in 13 EEN formulas, carrageenan in 12 and carboxymethyl 
cellulose and polysorbate 80 were present in eight and three formu-
las respectively. We therefore propose that authors making dietary 
recommendations based on the current epidemiological evidence, 
animal and in vitro experiments need to have supportive in vivo ev-
idence in human Crohn's disease before such wide ranging dietary 
restrictions are introduced to clinical practice.6,17 We propose that 
disease models are best utilised in understanding the mechanism 
of action of established dietary treatment, rather than in providing 
primary evidence to make recommendations on the role of diet in 
Crohn's disease onset and treatment.
Patients with Crohn's disease are often at high risk of undernu-
trition,13,34 particularly those with active disease, and are reported 
to have poor food-related quality of life and often introduce food 
aversions.35 The results of this study would help to remove a sig-
nificant degree of food-related anxiety. This study provides a list of 
macronutrients, along with their sources of origin, nonnutrient food 
ingredients and food additives, that health professionals can use as 
a guide to advise their patients on permitted food ingredients; at 
least within the amounts these are contained in EEN formulas and 
consumed during an EEN course.
A secondary aim of this study was to compare the macronu-
trient content of EEN formulas with the national DRV, the intake 
of heathy children following a Western diet from the UK NDNS 
and a group of children with Crohn's disease, whose dietary intake 
had been described in a previous study.21 Differences were ob-
served when comparing EEN formula macronutrient composition 
with the median intake of both the healthy children and children 
with Crohn's disease. One may assume that EEN works by limit-
ing the amount of sugars and total fat, and in particular saturated 
fat. However, the fact that EEN formulas have a wide variation in 
the content of these macronutrients and still demonstrate clinical 
effectiveness contradicts this assumption. Once again, subgroup 
analysis with inclusion of EEN formulas from RCTs retained in 
Cochrane meta-analysis mirrored the findings of the initial set of 
all formulas.
Here, we provide a list of food ingredients which are unlikely to 
be harmful, within the amounts these are consumed during an EEN 
course. However, we are unable to comment on food additives and 
other nonnutrient food ingredients which have been implicated in 
gut inflammation in Crohn's disease but are not present in at least 
one of the EEN formulas.18 For example, calcium propionate has 
been implicated in Crohn's disease in preclinical research 18 but it 
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is not present in EEN formulas. It is possible that such food ad-
ditives are important to Crohn's disease pathogenesis and future 
studies should explore whether their selective exclusion is associ-
ated with a therapeutic signal in Crohn's disease patients. Similarly, 
to the best of our knowledge, all EEN formulas were gluten and 
lactose-free. It is therefore possible that the mode of action of EEN 
is mediated by exclusion of gluten, lactose or other ingredients in 
food which coincide with the presence of gluten. In support of this 
claim, novel dietary treatments of Crohn's disease with early signals 
of clinical efficacy, including reduction of inflammatory markers, 
eliminate gluten and lactose intake.7,36 Similarly, a cross-sectional 
study in 1,647 patients with IBD showed that adherence to a glu-
ten-free diet was associated with improvement in gastrointestinal 
symptoms.37
Fibre has long been advocated as a beneficial nutrient for 
Crohn's disease patients despite well-designed RCTs failing to prove 
any profound benefit.3 However, despite their clinical effectiveness 
and amelioration of gut inflammation, the large majority of the EEN 
formulas analysed here (80%) lack any fibre. This observation does 
not mean that fibre is essentially harmful for patients with Crohn's 
disease but, certainly, its elimination does not exacerbate symp-
toms in patients with active Crohn's disease. However, it is worth 
reporting that of the few EEN formulas which contained fibre, the 
predominant ones were inulin, fructo-oligosaccharides, pectin and 
gum arabic which do not encompass the variable range of fibres 
included in our habitual diet.
There is extensive interest in the role of PUFA in the aetiopatho-
genesis of Crohn's disease and inflammatory bowel disease.38 High 
intake of n-6 pro-inflammatory PUFA has been associated with an 
increased risk of IBD onset.2 However, the wide range of fat content 
(ie 0% to 50%) in EEN formulas, the majority of which originates from 
n-6-containing vegetable oils, suggests that their role in disease ac-
tivity is likely negligible. This assumption is further supported from a 
recent Cochrane review.19
There are limitations to this study. The exact concentration of 
food additives in some EEN formulas were unavailable and would 
not be disclosed by the manufacturers of EEN formulas, despite 
authors’ requests. The fact, though, that food products for medical 
use are closely regulated by health and food standard authorities 
meant that we were able to obtain a large amount of nutritional in-
formation which is not normally available from the manufacturers 
of “ordinary” food. Although we provided a list of nutrients, food 
ingredients and food additives contained within EEN regimes, we 
are unable to comment on other food additives implicated in the 
pathogenesis of IBD which were not included in the composition 
of the EEN formulas described here. Furthermore, there may have 
been some changes in the composition of EEN formulas over the 
years. EEN formulas used in older studies may have had differ-
ent composition to those used in this analysis which is based on 
their current ingredients. It was also not possible to explore as-
sociations between the concentration of food additives within 
EEN formulas and the magnitude of clinical response to EEN. As 
mentioned above, this information was unavailable in most of the 
cases and the methods used to assess specific disease activity and 
biomarkers varied considerably between studies preventing more 
complex data synthesis on efficacy (Table S2). However, differen-
tial analysis between EEN formulas containing these food addi-
tives and others which do not, showed no difference in remission 
rates between these two groups, thus further challenging their 
role in disease management.
Although we performed an extensive literature search, there 
is also a possibility that we may have missed EEN formulas which 
were used for treatment of active Crohn's disease in routine clin-
ical practice but have never been described in a peer-reviewed 
publication.
Furthermore, in studies which used more than one EEN formulas, 
and which reported cumulative efficacy signals only, it was not pos-
sible to assign remission rates for each type of formula separately. 
However, we have not identified any study, with mixed use of EEN 
formulas, in which the authors reported variable efficacy signals ac-
cording to the type of EEN formula.
It is also important to acknowledge that a dietary component 
may play a different role in the initiation and the propagation of in-
flammation in Crohn's disease. For example, dietary fibre may well 
be protective against Crohn's disease onset 39 but play no role in 
disease management.3 While we are confident about the role of the 
food ingredients surveyed here in the context of Crohn's disease 
management, we are unable to make any comment about their role 
in Crohn's disease pathogenesis.
In conclusion, we provide a list of food ingredients which are un-
likely, in the amount provided within an EEN course, to represent sig-
nificant dietary triggers of Crohn's disease. This reduces a degree of 
food-related anxiety from patients with Crohn's disease and enables 
health professionals to provide informed, evidence-based advice to 
their patients. We also challenge perceptions formulated from in 
vitro and animal experiments regarding the role of dietary factors in 
Crohn's disease management and provide hints as to where future 
research in the area of food industrialisation and its role in Crohn's 
disease should be directed. Based on the findings of this analysis, 
we see no reason to advocate for a particular dietary restriction in 
Crohn's disease and challenge those advocating the alternative to 
provide data from clinical control trials.
ACKNOWLEDG EMENTS
Declaration of personal interests: K Gerasimidis received research 
grants, speakers' fees and had conference attendance paid by 
Nutricia, Nestle and Dr Falk. DRG has received speaker honoraria 
& travel grants from Takeda, Pfizer, Janssen, Ferring, Vifor and 
Monofer. JPS has received speaker's fees or travel support from 
Takeda, Monofer, Dr Falk, AbbVie, Ferring and Tillotts. RH has re-
ceived speakers/consultancy fees or conference support from 
Nutricia, Dr Falk, MSD Immunology and 4D Pharma. RKR has re-
ceived speaker's fees, travel support and/or participated in medical 
board meetings with Nestle, MSD Immunology, AbbVie, Dr Falk, 
Takeda, Napp, Mead Johnson, Nutricia and 4D Pharma. SM has par-
ticipated in medical board meetings with Pfizer.
946  |     LOGAN et AL.
FUNDING INFORMATION
ML & K Gkikas’ PhD studentships were funded in part by Nestle 
Health Science. VS, BN, JM, UZI do not have any relevant personal 
or funding conflicts to report.
AUTHORSHIP
Guarantor of the article: Konstantinos Gerasimidis.
Author contributions: ML was involved in the study design, liter-
ature search, data collection, statistical analysis and prepared the 
first draft of the manuscript; K Gkikas contributed to the literature 
search, data collection, statistical analysis and the preparation of the 
first draft of the manuscript; VS was involved in the study design, 
literature search and data collection; BN helped in the statistical 
analysis and the production of heatmaps; SM, RH, UZI, RKR all pro-
vided critical feedback, helped shape the research question, analysis 
of results and feedback at all stages of the manuscript preparation; 
DRG, JPS and JM contributed to collection and critical analysis of 
data following the paper's first review, offered feedback at all stages 
of the manuscript preparation and contributed to the write up of 
the revised manuscript; K Gerasimidis proposed the initial study de-
sign, edited critically the first draft for publication and supervised 
the overall research.
All authors reviewed the final version of the manuscript and 
agreed to its content prior submission.
ORCID
Michael Logan  https://orcid.org/0000-0003-3967-6123 
Konstantinos Gkikas  https://orcid.org/0000-0003-1581-6566 
Vaios Svolos  https://orcid.org/0000-0002-7785-4245 
Simon Milling  https://orcid.org/0000-0003-4384-5516 
Daniel R. Gaya  https://orcid.org/0000-0003-1942-7568 
John Paul Seenan  https://orcid.org/0000-0002-1524-1080 
Richard Hansen  https://orcid.org/0000-0002-3944-6646 
Umer Z. Ijaz  https://orcid.org/0000-0001-5780-8551 
Richard K. Russell  https://orcid.org/0000-0001-7398-4926 
Konstantinos Gerasimidis  http://orcid.
org/0000-0001-9432-2200 
R E FE R E N C E S
 1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and preva-
lence of inflammatory bowel disease in the 21st century: a system-
atic review of population-based studies. Lancet (London, England). 
2018;390:2769-2778.
 2. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of develop-
ing inflammatory bowel disease: a systematic review of the litera-
ture. Am J Gastroenterol. 2011;106:563-573.
 3. Wedlake L, Slack N, Andreyev HJ, Whelan K. Fiber in the treat-
ment and maintenance of inflammatory bowel disease: a system-
atic review of randomized controlled trials. Inflamm Bowel Dis. 
2014;20:576-586.
 4. Lev-Tzion R, Griffiths AM, Leder O, Turner D. Omega 3 fatty acids 
(fish oil) for maintenance of remission in Crohn's disease. Cochrane 
Database Syst Rev. 2014;2:Cd006320.
 5. Agus A, Denizot J, Thévenot J, et al. Western diet induces a 
shift in microbiota composition enhancing susceptibility to 
Adherent-Invasive E. coli infection and intestinal inflammation. Sci 
Rep. 2016;6:19032.
 6. Levine A, Sigall Boneh R, Wine E. Evolving role of diet in the 
pathogenesis and treatment of inflammatory bowel diseases. Gut. 
2018;67(9):1726-1738.
 7. Levine A, Wine E, Assa A, et al. Crohn's disease exclusion diet plus 
partial enteral nutrition induces sustained remission in a random-
ized controlled trial. Gastroenterology. 2019;157:440-450.
 8. Roberts CL, Keita AV, Duncan SH, et al. Translocation of Crohn's 
disease Escherichia coli across M-cells: contrasting effects of soluble 
plant fibres and emulsifiers. Gut. 2010;59:1331-1339.
 9. Chassaing B, Koren O, Goodrich JK, et al. Dietary emulsifiers im-
pact the mouse gut microbiota promoting colitis and metabolic syn-
drome. Nature. 2015;519:92-96.
 10. Gerasimidis K, Bryden K, Chen X, et al. The impact of food addi-
tives, artificial sweeteners and domestic hygiene products on the 
human gut microbiome and its fibre fermentation capacity. Eur J 
Nutr. 2019. [Epub ahead of print]. https://doi.org/10.1007/s0039 
4-019-02161 -8
 11. Albenberg L, Brensinger CM, Wu Q, et al. A diet low in red and 
processed meat does not reduce rate of crohn's disease flares. 
Gastroenterology. 2019;157:128-136.
 12. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of 
ECCO/ESPGHAN on the medical management of pediatric Crohn's 
disease. J Crohns Colitis. 2014;8:1179-1207.
 13. Cameron FL, Gerasimidis K, Papangelou A, et al. Clinical progress 
in the two years following a course of exclusive enteral nutrition 
in 109 paediatric patients with Crohn's disease. Aliment Pharmacol 
Ther. 2013;37:622-629.
 14. Gerasimidis K, Nikolaou CK, Edwards CA, McGrogan P. Serial fecal 
calprotectin changes in children with Crohn's disease on treatment 
with exclusive enteral nutrition: associations with disease activ-
ity, treatment response, and prediction of a clinical relapse. J Clin 
Gastroenterol. 2011;45:234-239.
 15. Logan M, Ijaz UZ, Hansen R, Gerasimidis K, Russell RK. Letter: 
reproducible evidence shows that exclusive enteral nutrition 
significantly reduces faecal calprotectin concentrations in 
children with active Crohn's disease. Aliment Pharmacol Ther. 
2017;46:1119-1120.
 16. Codex Alimentarius Commission. Codex Alimentarius: General Standard 
for Food Additives - CODEX STAN 192-1995, last revision 2019. Rome 
& Geneva: Food and Agriculture Organisation of the United Nations 
(FAO) & World Health Organisation (WHO); 2019. http://www.fao.
org/gsfao nline /docs/CXS_192e.pdf. Accessed September 30, 2019.
 17. Marion-Letellier R, Amamou A, Savoye G, Ghosh S. Inflammatory 
bowel diseases and food additives: to add fuel on the flames!. 
Nutrients. 2019;11:E1111.
 18. Ormsby MJ, Logan M, Johnson SA, et al. Inflammation associated 
ethanolamine facilitates infection by Crohn's disease-linked adher-
ent-invasive Escherichia coli. EBioMedicine. 2019;43:325-332.
 19. Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. 
Enteral nutritional therapy for induction of remission in Crohn's dis-
ease. Cochrane Database Syst Rev. 2018;4:Cd000542.
 20. Public Health England. NDNS: Results from Years 7 and 8 
(Combined). https://www.gov.uk/gover nment /stati stics /ndns-re-
sul ts-from-years -7-and-8-combined
 21. Tsiountsioura M, Wong JE, Upton J, et al. Detailed assessment of 
nutritional status and eating patterns in children with gastrointes-
tinal diseases attending an outpatients clinic and contemporary 
healthy controls. Eur J Clin Nutr. 2014;68:700-706.
 22. Englyst HN, Hudson GJ. The classification and measurement of di-
etary carbohydrates. Food Chem. 1996;57:15-21.
 23. Lecomte M, Couëdelo L, Meugnier E, et al. Dietary emulsifiers from 
milk and soybean differently impact adiposity and inflammation in 
     |  947LOGAN et AL.
association with modulation of colonic goblet cells in high-fat fed 
mice. Mol Nutr Food Res. 2016;60:609-620.
 24. Karner M, Kocjan A, Stein J, et al. First multicenter study of modi-
fied release phosphatidylcholine "LT-02" in ulcerative colitis: a ran-
domized, placebo-controlled trial in mesalazine-refractory courses. 
Am J Gastroenterol. 2014;109:1041-1051.
 25. Stremmel W, Ehehalt R, Autschbach F, Karner M. Phosphatidylcholine 
for steroid-refractory chronic ulcerative colitis: a randomized trial. 
Ann Intern Med. 2007;147:603-610.
 26. Lomer MC, Thompson RP, Powell JJ. Fine and ultrafine particles of 
the diet: influence on the mucosal immune response and associa-
tion with Crohn's disease. Proc Nutr Soc. 2002;61:123-130.
 27. Butler M, Boyle JJ, Powell JJ, Playford RJ, Ghosh S. Dietary mi-
croparticles implicated in Crohn’s disease can impair macrophage 
phagocytic activity and act as adjuvants in the presence of bacterial 
stimuli. Inflamm Res. 2007;56:353-361.
 28. Ruiz PA, Morón B, Becker HM, et al. Titanium dioxide nanoparticles 
exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. 
Gut. 2017;66:1216-1224.
 29. Bettini S, Boutet-Robinet E, Cartier C, et al. Food-grade TiO2 im-
pairs intestinal and systemic immune homeostasis, initiates preneo-
plastic lesions and promotes aberrant crypt development in the rat 
colon. Sci Rep. 2017;7:40373.
 30. Lomer MCE, Grainger SL, Ede R, et al. Lack of efficacy of a reduced 
microparticle diet in a multi-centred trial of patients with active 
Crohn's disease. Eur J Gastroenterol Hepatol. 2005;17:377-384.
 31. Jiang Z, Zhao M, Zhang H, Li Y, Liu M, Feng F. Antimicrobial emulsi-
fier-glycerol monolaurate induces metabolic syndrome, gut micro-
biota dysbiosis, and systemic low-grade inflammation in low-fat diet 
fed mice. Mol Nutr Food Res. 2018;62:1700547C.
 32. Nickerson KP, McDonald C. Crohn's disease-associated adher-
ent-invasive Escherichia coli adhesion is enhanced by exposure 
to the ubiquitous dietary polysaccharide maltodextrin. PLoS ONE. 
2012;7:e52132.
 33. Munyaka PM, Sepehri S, Ghia JE, Khafipour E. Carrageenan gum 
and adherent invasive Escherichia coli in a piglet model of inflamma-
tory bowel disease: impact on intestinal mucosa-associated micro-
biota. Front Microbiol. 2016;7:462.
 34. Gerasimidis K, McGrogan P, Edwards CA. The aetiology and impact 
of malnutrition in paediatric inflammatory bowel disease. J Hum 
Nutr Diet. 2011;24:313-326.
 35. Gerasimidis K, McGrogan P, Hassan K, Edwards CA. Dietary modifi-
cations, nutritional supplements and alternative medicine in paedi-
atric patients with inflammatory bowel disease. Aliment Pharmacol 
Ther. 2008;27:155-165.
 36. Svolos V, Hansen R, Nichols B, et al. Treatment of active Crohn's 
disease with an ordinary food-based diet that replicates exclusive 
enteral nutrition. Gastroenterology. 2019;156:1354-1367.e6
 37. Herfarth HH, Martin CF, Sandler RS, Kappelman MD, Long MD. 
Prevalence of a gluten-free diet and improvement of clinical symp-
toms in patients with inflammatory bowel diseases. Inflamm Bowel 
Dis. 2014;20:1194-1197.
 38. Mozaffari H, Daneshzad E, Larijani B, Bellissimo N, Azadbakht L. 
Dietary intake of fish, n-3 polyunsaturated fatty acids, and risk of 
inflammatory bowel disease: a systematic review and meta-analysis 
of observational studies. Eur J Nutr. 2020;59:1-17.
 39. Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective 
study of long-term intake of dietary fiber and risk of Crohn's disease 
and ulcerative colitis. Gastroenterology. 2013;145:970-977.
SUPPORTING INFORMATION
Additional supporting information will be found online in the 
Supporting Information section.
How to cite this article: Logan M, Gkikas K, Svolos V, et al. 
Analysis of 61 exclusive enteral nutrition formulas used in the 
management of active Crohn’s disease—new insights into 
dietary disease triggers. Aliment Pharmacol Ther. 
2020;51:935–947. https://doi.org/10.1111/apt.15695
